Living Homeopathy International Ltd.

F-1/A amended

Living Homeopathy International Ltd. is conducting an initial public offering (IPO) of 3,750,000 Class A Ordinary Shares, with an estimated price range of $4.00 to $6.00 per share. The company, structured as a Cayman Islands holding company, operates through its Hong Kong subsidiary and generates all revenue from Hong Kong. The filing includes adjustments to share capital following an Adjustment Issuance, increasing total shares from 18,000,000 to 23,750,000. The IPO is contingent on Nasdaq approval, and the company highlights risks related to PRC regulatory actions and geopolitical uncertainties.

F-1/A amended

Living Homeopathy International Ltd. is conducting an initial public offering (IPO) of 1,250,000 Class A ordinary shares, with an estimated price range of $4.00 to $6.00 per share. The offering is contingent on Nasdaq's approval for listing. The company, structured as a Cayman Islands holding company, operates through its Hong Kong subsidiary. The filing emphasizes risks related to PRC regulatory actions, Hong Kong's legal environment, and uncertainties around compliance with Chinese laws, including cybersecurity reviews and overseas listing regulations. Legal counsel confirms current compliance but highlights ongoing regulatory risks.

F-1/A amended

Living Homeopathy International Ltd. filed an amended F-1/A registration statement for its initial public offering of 1,250,000 Class A ordinary shares, with an estimated price range of $4.00 to $6.00 per share. The offering is contingent on Nasdaq's approval for listing. The company, a Cayman Islands holding company, operates through its Hong Kong subsidiary and emphasizes its separation from mainland China operations. The filing includes expanded disclosures on regulatory risks related to PRC government actions and potential challenges under Chinese securities laws.

F-1/A amended

Living Homeopathy International Ltd. is conducting an initial public offering (IPO) of 1,250,000 Class A ordinary shares, with an estimated price range of $4.00 to $6.00 per share. The offering is contingent on Nasdaq's approval for listing. The company, structured as a Cayman Islands holding company, operates through its Hong Kong subsidiary and emphasizes its lack of operations in mainland China. The filing highlights risks related to regulatory scrutiny, geopolitical tensions, and uncertainties around Chinese government interventions in Hong Kong and overseas listings.

F-1 filed

Living Homeopathy International Ltd. is conducting an initial public offering (IPO) of 1,250,000 Class A ordinary shares, with an estimated price range of $4.00 to $6.00 per share. The company, structured as a Cayman Islands holding company, operates through its Hong Kong subsidiary and generates revenue exclusively from Hong Kong. The IPO is contingent on Nasdaq's approval for listing, and the company emphasizes its status as an emerging growth company with reduced reporting requirements. Shareholders hold Class A and B shares with differing voting rights, and the offering does not involve direct equity in its mainland China operations.

DRS/A amended

Living Homeopathy International Ltd. is conducting an initial public offering (IPO) of Class A ordinary shares, aiming to list on the Nasdaq Capital Market under the symbol LHI. The offering is contingent on Nasdaq's approval, with an estimated price range of $[●] to $[●] per share. The company, structured as a Cayman Islands holding company, operates through its Hong Kong subsidiary, generating revenue exclusively from Hong Kong. It emphasizes its status as an emerging growth company with reduced reporting requirements and highlights regulatory risks related to PRC-Hong Kong governance and cybersecurity laws.

DRS/A amended

Living Homeopathy International Ltd. is conducting an initial public offering (IPO) of $[●] in Class A Ordinary Shares, aiming to list on Nasdaq. The company, a Cayman Islands holding company, operates through its Hong Kong subsidiary. The offering is contingent on Nasdaq approval, with risks including regulatory uncertainties in Hong Kong and mainland China. The filing emphasizes the company's structure, share capital details, and compliance with U.S. and PRC regulations.

DRS/A amended

Living Homeopathy International Ltd. has filed a DRS/A registration statement for an initial public offering of Class A ordinary shares, targeting a Nasdaq listing. The filing highlights the company's structure as a Cayman Islands holding company with operations in Hong Kong, emphasizing its exclusion from mainland China operations. Key additions include detailed analyses of cybersecurity and overseas listing regulations, along with heightened risk disclosures regarding PRC government interventions and regulatory uncertainties.

DRS filed

Living Homeopathy International Ltd. is preparing for its initial public offering (IPO) of Class A Ordinary Shares, aiming to list on the Nasdaq Capital Market. The company, structured as a Cayman Islands holding company with operations in Hong Kong, emphasizes its status as an emerging growth company. The offering is contingent on Nasdaq's approval, and the filing highlights regulatory uncertainties related to PRC and Hong Kong laws, including potential government interventions, cybersecurity reviews, and compliance with China's Overseas Listing Trial Measures. The prospectus underscores significant risks, including the possibility of listing denial, regulatory changes, and operational disruptions.